A US study observed a large increase in healthcare costs in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC and BM from 2012 to 2015, compared with patients with metastases at other sites [14]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.